ISR-AEs over the EEP Erenumab, mg 70 (N=2128)a 140 (N=1198)a Subjects who experienced an ISR-AE, n 130 (6.1) 50 (4.2) Total time at risk summed across subjects, years 1738 649 Exposure-adjusted subject incidence rate per 100subject-yearssubject-years7.57.7 who received >1 dose level were counted in both dose levels.
In safety results, regardless of the UGT1A1 genotype, the subject incidence of severe neutropenia successively decreased in the second and third treatment cycles.
Respiratory adverse events occurring at a by-subject incidence rate of ≥3.0% in any of the years are given in Table 4.
In the first US study of this subject, leukaemia incidence in SEER registry data was recently examined in more rural counties that had experienced the largest population influxes (Wartenberg et al, 2004).
In the Magpie study which had the largest study group of over 5000 subjects, the incidence of the two adverse side effects was roughly the same, around 1% [ 9].
Compared to HPV-negative subjects, the incidence of HSIL or above neoplasia in HPV-positive subjects was significantly higher (0.0194 vs 0.0007), but this was not true in the Atypia and LSIL groups.
Preliminary sample size calculations prior to this pilot study suggested the need for a sample size as low as 932 subjects (25% incidence rate, 30% relative risk reduction, 5% type I error rate, and 80% power) to as high as 8604 subjects (10% incidence rate, 20% relative risk reduction, 5% type I error rate, and 90% power) for a full-scale multicentre RCT.
We followed up vital and residential status of subjects and incidence of cancer until the end of 1999.
When evaluated in a larger cohort of subjects, the incidence of romiplostim immunogenicity may be influenced by supportive therapies, severity of disease states, and genetic factors.
In the 20 obese subjects, the incidence of AMS was significantly higher than in those with no AMS (85% vs. 15%, p = 0.002).> -wrap-foot> *Significantly different between AMS and non-AMS groups.
To more efficiently control for confounding by the two most important risk factors for Parkinson's disease, we then individually matched five randomly selected control subjects (i.e., individuals without Parkinson's disease at the index date) from the Central Population Registry by sex and year of birth to each case subject, using incidence-density sampling (17).
